Print Page      Close Window     

Press Release

Spark Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Progress

Work on U.S. Biologics License Application (BLA) for investigational voretigene neparvovec is complete

Interim results from SPK-7001 Phase 1/2 clinical trial in choroideremia reported; continuing enrollment targeting participants at earlier stage of disease

PHILADELPHIA, May 09, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced financial results for the first quarter of 2017 and recent business progress.

“I’m pleased to announce that our work on the rolling BLA for voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease is now complete. The application formally will be submitted to the FDA next week,” said Jeffrey D. Marrazzo, chief executive officer. “We are excited to reach this major milestone, and will now shift our immediate regulatory focus to completing the Marketing Authorization Application submission for Europe by the end of July. Today, we report interim results of our second investigational gene therapy for a retinal disease, SPK-7001 in choroideremia, and that we plan to provide an initial update on the Phase 1/2 trial for SPK-8011 in hemophilia A in July or August 2017.”

Recent highlights

Advanced investigational voretigene neparvovec for the treatment of biallelic RPE65-mediated IRD:

• Progressed regulatory submissions in U.S. and EU

  • U.S. BLA is complete and ready for submission next week

Announced interim results of investigational SPK-7001 for choroideremia Phase 1/2 clinical trial:

• Reported interim safety results for the first 10 participants with later-stage disease

  • No reported product-related serious adverse events (SAEs) and one procedure-related SAE

• As of the March 29, 2017 data cutoff, interim efficacy analysis of the first 10 participants in the Phase 1/2 clinical trial did not show consistent and conclusive evidence of effect at the duration of follow-up in later-stage participants

  • However, non-significant differences between the injected and control eye were observed on one or more endpoints in four of the 10 participants in favor of the injected eye

• Expanded enrollment of the second dose cohort with focus on participants with earlier-stage disease

  • Three of the five participants already have been enrolled

Reported updated data from investigational SPK-9001 for hemophilia B Phase 1/2 clinical trial at Hemostasis and Thrombosis Research Society 2017 Scientific Symposium:

• No SAEs have been reported to date, including no factor IX inhibitors and no thrombotic events

• Since vector administration, as of data cutoff of March 24, 2017, among the 10 participants, the annualized infusion rate had been reduced by 99 percent, and the annualized bleeding rate had been reduced by 96 percent

  • Nine of the 10 infused participants had not taken any factor IX concentrates to prevent or control bleeding events
  • Mean steady-state factor IX activity level post-12 weeks treatment for the 10 participants was a sustained 33 percent

• Two participants who experienced an asymptomatic, transient elevation in liver enzymes or a decline in FIX activity and received a tapering dose of oral corticosteroids, have completed their steroid taper. Importantly, both participants, now at 14 weeks and eight weeks post-cessation of steroids, have shown stable factor IX activity levels

  • Neither participant has experienced a bleed nor taken factor IX concentrates

Bolstered organizational capabilities and human capital:

• Continued preparations for potential introduction of investigational voretigene neparvovec in U.S. and EU

• Continued to grow our team across all disciplines, with the number of employees now at more than 240

• Balance sheet remains strong, with $285.4 million in cash and cash equivalents and marketable securities at March 31, 2017

Financial results for the quarter ended March 31, 2017

In each of the three months ended March 31, 2017 and 2016, we recognized $1.3 million of revenue associated with our Pfizer collaboration.

Spark Therapeutics’ research and development expenses for the three months ended March 31, 2017 were $32.7 million, compared with $18.2 million for the three months ended March 31, 2016. The $14.5 million increase was due to an $11.4 million increase in internal research and development expenses, primarily due to significantly increased headcount, and an increase of $3.1 million in external research and development, primarily from an increase of $1.3 million in expenses related to studies to support and certain launch preparation activities for voretigene neparvovec, and an increase in our other clinical programs of $1.2 million and $0.6 million related to our other product candidates.

General and administrative expenses for the three months ended March 31, 2017 were $21.4 million, compared with $8.9 million for the three months ended March 31, 2016. The $12.5 million increase was primarily due to an increase of $6.3 million in salaries and related costs, including stock-based compensation, due to increased headcount, and an increase of $6.2 million in launch preparation activities for voretigene neparvovec, legal and patent expenses, professional fees and other operating costs.

Our net loss applicable to common stockholders for the three months ended March 31, 2017 was $52.3 million, or $1.70 basic and diluted net loss per common share, as compared with a net loss applicable to common stockholders of $25.6 million, or $0.95 basic and diluted net loss per common share for the three months ended March 31, 2016.

As of March 31, 2017, we had cash and cash equivalents and marketable securities of $285.4 million, with 31.1 million shares outstanding.

Conference call details
Spark Therapeutics will host a conference call and audio webcast, today, Tuesday, May 9, at 8:30 a.m. ET, to discuss corporate and financial results for the quarter that ended March 31, 2017. The call can be accessed by dialing the numbers below or by visiting the “Investors” section at www.sparktx.com.

U.S. Dial-in Number: (855) 851-4526
International Dial-in Number: (720) 634-2901
Passcode: 13840065

A replay of the call will be available for one week following the call by dialing the numbers below or also available on our website.

Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Passcode: 13840065

About Spark Therapeutics
Spark Therapeutics, a fully integrated company, strives to challenge the inevitability of genetic disease by discovering, developing, and delivering gene therapies that address inherited retinal diseases (IRDs), neurodegenerative diseases, as well as diseases that can be addressed by targeting the liver. Our validated platform successfully has delivered proof-of-concept data with investigational gene therapies in the retina and liver. Our most advanced investigational candidate, voretigene neparvovec, in development for the treatment of biallelic RPE65-mediated IRD, has received orphan designations in the U.S. and European Union, and breakthrough therapy designation in the U.S. The pipeline also includes SPK-7001 in a Phase 1/2 trial for choroideremia, and two hemophilia development programs: SPK-9001 (which also has received both breakthrough therapy and orphan product designations by the FDA, and access to the PRIority MEdicines (PRIME) Program by the EMA) in a Phase 1/2 trial for hemophilia B being developed in collaboration with Pfizer, and SPK-8011, in a Phase 1/2 trial for hemophilia A to which Spark Therapeutics retains global commercialization rights. To learn more about us and our growing pipeline, visit www.sparktx.com.

Cautionary note on forward-looking statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's product candidates, including voretigene neparvovec, SPK-7001, SPK-9001 and SPK-8011. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that: (i) our BLA being submitted to the FDA may not be accepted, or, if accepted, may not be approved;  (ii) the data from our Phase 3 clinical trial of voretigene neparvovec may not support labeling for all biallelic RPE65 mutations other than Leber congenital amaurosis (LCA); (iii) the improvements in functional vision demonstrated by voretigene neparvovec in our clinical trials may not be sustained over extended periods of time; (iv) interim data from our SPK-7001 Phase 1/2 clinical trial, including data to be generated from our recently expanded cohort, may not support further development of this product candidate; (v) preclinical results for our product candidate, SPK-8011, for hemophilia A may not translate to humans in clinical trials; (vi) our lead SPK-FIX product candidate, SPK-9001, may not produce sufficient data in our Phase 1/2 clinical trial to warrant further development; and (vii) any one or more of our product candidates in preclinical or clinical development will not successfully be developed and commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" section, as well as discussions of potential risks, uncertainties and other important factors, in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other filings we make with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Spark undertakes no duty to update this information unless required by law.

Spark Therapeutics, Inc.
Consolidated Balance Sheets
(Unaudited)
       
  December 31,
 2016
  March 31,
 2017
Assets      
Current assets:      
Cash and cash equivalents $ 58,923,097     $ 27,495,174  
Marketable securities 237,242,655     226,199,646  
Other receivables 16,780,917     5,946,802  
Prepaid expenses and other current assets 1,647,008     3,713,708  
Total current assets 314,593,677     263,355,330  
Marketable securities 21,900,129     31,700,984  
Property and equipment, net 19,794,306     23,097,630  
Acquired in-process research and development 15,490,000     14,950,531  
Goodwill 1,160,104     1,119,564  
Other assets 924,579     853,510  
Total assets $ 373,862,795     $ 335,077,549  
Liabilities and Stockholders’ Equity      
Current liabilities:      
Accounts payable $ 9,928,737     $ 14,021,116  
Accrued expenses and other 13,826,920     9,097,776  
Current portion of long-term debt 302,013     304,473  
Current portion of deferred rent 771,196     1,140,735  
Current portion of deferred revenue 5,168,674     5,168,674  
Total current liabilities 29,997,540     29,732,774  
Long-term debt 1,224,003     1,146,956  
Long-term deferred rent 7,498,419     11,086,281  
Long-term deferred revenue 3,865,885     2,591,418  
Deferred tax liability 1,000,235     965,401  
Total liabilities 43,586,082     45,522,830  
Stockholders’ equity:      
Preferred stock, $0.001 par value. Authorized, 5,000,000 shares; no shares issued or outstanding      
Common stock, $0.001 par value. Authorized, 150,000,000 shares; 30,873,430 shares issued and 30,864,224 shares outstanding at December 31, 2016; 31,086,809 shares issued and 31,077,603 shares outstanding at March 31, 2017 30,874     31,087  
Additional paid-in capital 583,973,682     596,436,232  
Accumulated other comprehensive loss (794,296 )   (1,689,721 )
Treasury stock, at cost, 9,206 shares at December 31, 2016 and March 31, 2017 (552,636 )   (552,636 )
Accumulated deficit (252,380,911 )   (304,670,243 )
Total stockholders’ equity 330,276,713     289,554,719  
Total liabilities and stockholders’ equity $ 373,862,795     $ 335,077,549  


Spark Therapeutics, Inc.
Consolidated Statements of Operations
(Unaudited)
   
  Three months ended March 31,
  2016   2017
Revenues $ 1,288,628     $ 1,274,467  
Operating expenses:      
Research and development 18,251,900     32,735,033  
General and administrative 8,873,861     21,413,818  
Total operating expenses 27,125,761     54,148,851  
Loss from operations (25,837,133 )   (52,874,384 )
Interest income 260,422     585,052  
Net loss $ (25,576,711 )   $ (52,289,332 )
Basic and diluted net loss per common share $ (0.95 )   $ (1.70 )
Weighted average basic and diluted common shares outstanding 26,807,380     30,771,867  

 

Investor Contact:
Ryan Asay
Ryan.asay@sparktx.com
(215) 239-6424

Media Contact:
Monique da Silva
Monique.dasilva@sparktx.com
(215) 282-7470

Primary Logo

Spark Therapeutics, Inc.